|
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Novartis; Pfizer; Roche |
Research Funding - Amgen (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst); Vifor Pharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |